Portfolio

Fastinov
Biotechnology
EGF II | EGF III | EGF IV

Invested in
2022

INVESTMENT RATIONALE

Development of differentiating technology to fight against antimicrobial resistance.

STRATEGY

Support solution development and go-to-market strategy

Please note, your browser is out of date.
For a good browsing experience we recommend using the latest version of Chrome, Firefox, Safari, Opera or Internet Explorer.